ER-100 and Yamanaka Factors: The Bid to Restore Vision by Reprogramming Cells

A treatment for damaged eye cells has to preserve something an aging-clock headline can overlook: those cells still need to know how to be part of an eye.

That is the central challenge behind ER-100, Life Biosciences’ experimental gene therapy. Its strategy uses three Yamanaka factors—OCT4, SOX2 and KLF4—to try to restore healthier function in retinal nerve cells. It borrows from the discovery that adult cells can be reprogrammed, but aims to stop short of turning them into stem cells. Life Biosciences’ description of the approach.

The company announced the first participant dosed in its Phase 1 trial on June 9, 2026. The program includes open-angle glaucoma and non-arteritic anterior ischemic optic neuropathy, or NAION. Safety and tolerability are its central purpose, with additional assessments of visual function. That moved the approach into human testing; it did not settle whether it restores sight. Clinical-entry announcement.

To understand what makes the experiment important, start with the distinction between making a cell versatile again and helping it perform the job it already has.

What Yamanaka factors actually changed

In their landmark 2006 study, Kazutoshi Takahashi and Shinya Yamanaka generated induced pluripotent stem cells from mouse fibroblasts. They introduced four factors: OCT3/4, SOX2, KLF4 and c-MYC, commonly shortened to OSKM. OCT3/4 is another name for OCT4.

These are transcription factors: proteins involved in regulating gene activity. The experiment showed that a mature cell’s identity was changeable. Under the appropriate laboratory conditions, cells that had already specialized could acquire an embryonic-stem-cell-like state. It did not show that a person could be made younger.

Pluripotent describes the capacity to produce many different specialized cell types. Kyoto University’s Center for iPS Cell Research and Application provides an accessible explanation of Yamanaka factors and iPS cells, including the subsequent generation of human iPS cells in 2007.

That discovery opened a powerful route for cell research. But a nerve cell inside an eye has a different obligation from a stem cell growing in a dish. Its specialized identity is part of what a treatment needs to preserve.

ER-100 is aiming for restoration, not a fresh start

The company identifies ER-100 as AAV2-OSK: a gene-therapy approach using an adeno-associated viral vector to deliver instructions for OCT4, SOX2 and KLF4 expression. Its targets are retinal ganglion cells, the neurons whose signals carry visual information toward the brain. This is not an infusion of laboratory-grown stem cells or a peptide supplement. ER-100 program description.

The proposed intervention is partial epigenetic reprogramming. Epigenetic regulation helps determine how genetic instructions are used. The aim is to shift some age- or injury-associated patterns toward a healthier state while retaining the cell’s specialized role. Delivery introduces genetic instructions; the intended effect is on gene regulation rather than editing the cell’s existing DNA sequence. Platform explanation.

A useful analogy is restoring a specialist’s working methods without dismissing the specialist. The analogy describes the ambition, not a result already established in patients.

For a treatment, “younger” needs a practical meaning. A cell that looks different in a molecular analysis has not necessarily become better at sending a useful signal.

Removing the fourth factor does not settle the safety question

ER-100’s three-factor approach leaves out c-MYC. That matters, but it does not create an automatic stopping point.

In follow-up work published online in 2007, Masato Nakagawa and colleagues described the tumorigenicity associated with reactivation of the c-Myc retrovirus in earlier mouse experiments. They also demonstrated that both mouse and human fibroblasts could be reprogrammed into iPS cells without MYC. The MYC-free reprogramming study.

The implication is precise: three factors do not, by definition, mean partial reprogramming. The absence of MYC alone cannot certify that a cell will retain its identity. The tissue, delivery system and control of expression remain essential parts of the experiment.

This is not evidence that ER-100 causes tumors. It is why “we removed one factor” cannot substitute for testing the behavior of the complete treatment.

The studies behind the clinical idea

The research pathway is more informative than treating every reprogramming result as evidence for the same product.

Partial reprogramming in mice, 2016. In a Cell study, Alejandro Ocampo and colleagues reported improved age-associated features and survival in a premature-aging mouse model using cyclic OSKM expression. They also found better recovery after pancreatic and muscle injury in older, normally aging mice. Those are distinct experiments—not a demonstration of human lifespan extension.

The same paper made control consequential. Continuous expression produced severe harm in one setting, while a higher-copy cyclic system produced teratomas, tumors containing multiple tissue types. Outcomes depended on how the factors were expressed. This was foundational work using four factors, not a clinical test of ER-100.

OSK in the mouse eye, 2020. Yuancheng Lu and colleagues’ Nature paper reported that OSK expression in retinal ganglion cells shifted molecular aging patterns, promoted axon regeneration after injury and improved visual outcomes in mouse glaucoma and aging models. The effects required TET1 and TET2, enzymes involved in DNA demethylation.

That combination—molecular change alongside functional measurements—is what makes the study relevant to recovery. It connects a proposed mechanism with something tissue does. It still does not establish an equivalent benefit in a human eye.

A primate step, 2023. Life Biosciences’ ARVO conference announcement described an OSK approach in a nonhuman-primate model of NAION. Following experimentally induced injury, treated eyes showed better pattern electroretinogram responses and more healthy axon bundles than controls, according to the company.

A pattern electroretinogram measures retinal electrical responses. It is not a report of people reading more lines on an eye chart. The announcement also does not supply a full numerical dataset or sample size. It is a sponsor’s account of conference findings, not a peer-reviewed human efficacy trial.

These experiments support a reason to investigate. They are not interchangeable replications: their species, factors, delivery systems and injuries differ.

Why the eye gives rejuvenation a demanding test

Glaucoma damages the optic nerve, often progressively narrowing peripheral vision. The National Eye Institute explains that established treatment can help stop further deterioration but does not undo vision already lost. Protecting remaining function is valuable; recovering lost function would address a different need. NEI’s glaucoma overview.

For that reason, an eye experiment need not prove that an entire person has become biologically younger to matter. A durable, clinically meaningful improvement in vision would be important on its own.

But a development program has several questions to answer:

This is an editorial framework for interpreting the research, not a list of completed ER-100 findings. A treatment can become useful before every mechanistic detail is resolved. Conversely, a persuasive mechanism can fail to produce enough benefit for patients.

The FDA describes Phase 1 as an early stage centered on safety and dosage, while also gathering initial information that informs later studies. Larger and longer trials help test treatment benefit and less common or delayed harms. Life Biosciences’ January 2026 IND-clearance announcement concerned permission to begin clinical testing—not approval to market a rejuvenation medicine. FDA’s clinical-research guide.

RSD’s earlier ER-100 article focuses on the initial reported human observations. This follow-up explains the biological strategy behind that clinical program; it is not announcing a new efficacy result.

The important promise is a cell that still works

There are reasons to take this research seriously without turning it into an all-purpose theory of aging. The experiments ask whether some features of a damaged cell’s state can be changed while preserving the specialization that gives the cell its value. They also expose how much the answer can depend on experimental conditions.

The commercial context belongs in view. The 2020 Nature paper’s disclosures include patents and financial relationships involving several authors and a Life Biosciences company. Those disclosures do not decide whether the findings are correct; they help readers distinguish the research evidence from the commercial ambition built around it.

The Yamanaka discovery showed that mature cellular identity need not be permanent. ER-100 explores a more constrained possibility: that useful recovery might be achieved without taking that identity apart.

The most meaningful finish line is therefore not a cell that can become anything. It is an eye cell that can do its own job better—and a person whose vision benefits as a result.

---

Evidence and editorial note: This is a mechanism-focused research explainer, not a new clinical-results report or treatment recommendation. Some original papers were accessible only through abstracts and publisher previews; those limits are recorded in the research package. The October 8 interim release and complete current trial-registry record could not be independently rechecked for this article, so their detailed interim figures are not repeated. This AI-assisted draft has not yet received independent medical or scientific review.